AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01582893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P210H
Description: Dialysis
Study NCT04617626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Single dose of azithromycin suspension
Study NCT01112917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaTech Convertible Vena Cava Filter
Description: Prevention of Pulmonary Embolism
Study NCT01112917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vena Cava Filter Conversion
Description: Conversion of VenaTech Convertible filter to open configuration.
Study NCT00815659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
Study NCT01912170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Study NCT01912170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Study NCT01216826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
Study NCT04138797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiological exploration
Description: Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval
Study NCT04138797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Biosemi
Description: Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
Study NCT00755651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
Study NCT00755651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy
Description: Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
Study NCT03035266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
Study NCT03035266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Standard of care for post-operative condition
Study NCT02894112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-fat milk
Description: 1 serving of non-fat fluid milk
Study NCT02894112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate control beverage
Description: 1 serving of carbohydrate control beverage (Carbohydrate powder + water)
Study NCT02894112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caloric control beverage
Description: 1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
Study NCT01178671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Study NCT01178671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Study NCT01178671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Study NCT01178671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
Study NCT00573885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given orally
Study NCT00573885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02910661 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last \~90 min. and be audio-recorded. An observer will take field notes.
Study NCT00979784 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Better Weight
Description: Standard cognitive behavioral treatment focused on dietary \& exercise behavior
Study NCT00979784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Weight & Better Sleep
Description: Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
Study NCT02253303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: midline incision or off-midline incision
Description: Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
Study NCT02253303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: midline incision or off-midline incision
Description: Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
Study NCT02316366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astoflo Plus fluid warmer
Description: A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
Study NCT04417374 — intervention group
Intervention type: OTHER
Intervention: Description of groups caracteristics
Description: Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
Study NCT01702597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)
Description: Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
Study NCT01702597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients will receive a standardized physical therapy.
Study NCT03252951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: Different Anal Sphincter Exercise Types for muscle hypertrophy
Study NCT03252951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentric Training
Description: Different Anal Sphincter Exercise Types for muscle hypertrophy
Study NCT03252951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isometric Training
Description: Different Anal Sphincter Exercise Types for muscle hypertrophy
Study NCT03252951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Standard of Care Biofeedback Training
Study NCT02145689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
Study NCT04571866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-glucan bread
Description: Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
Study NCT04571866 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Beta-glucan bread
Description: Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
Study NCT04223869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal treatment
Description: scaling and root planing were performed
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 6
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 12
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 18
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 24,
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 30
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 6
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 12
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 18
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 24
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 30
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox intramuscularly
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Study NCT02074163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox subdermally
Description: Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Study NCT00548054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent killed oral cholera vaccine
Description: Oral, 1.5 ml, given 2 times at least 14 days apart
Study NCT00548054 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Killed Escherichia coli K12 placebo
Description: oral, 1.5 ml per dose
Study NCT04334434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: 15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist
Study NCT02168842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isradipine
Description: Oral capsules Isradipine IR, up to 10 mg, taken twice daily
Study NCT02168842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Isradipine)
Description: Sugar Pill manufactured to look like Isradipine but has no active ingredients
Study NCT02547233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel
Study NCT02547233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study NCT00975351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C5-labelled 5-methyltetrahydrofolic acid
Description: one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention.
Study NCT02262923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Study NCT04327492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP
Description: peak wave velocity; gray weale plaque classification
Study NCT00638131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
Study NCT00638131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bosentan
Description: 62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
Study NCT00551460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study NCT00551460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Study NCT00551460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT00551460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00551460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Study NCT01890304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxil
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Study NCT02489903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT02587468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice Plus+(R)
Description: before-after comparison of plasma phenolics
Study NCT00133146 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grass MATA MPL
Study NCT00133146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL
Study NCT01272804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319
Description: Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
Study NCT01272804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
Study NCT00885651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolole (Selo-Zok ®)
Description: Tablets, 200 mg, once a day, 10 days
Study NCT00885651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolole (Selo-Zok ®)
Description: Tablets, 200 mg, once a day, 10 days
Study NCT00885651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00885651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02803892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL
Study NCT02803892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.
Study NCT02803892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
Study NCT02803892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
Study NCT03155256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided injection of coils with cyanoacrylate
Description: First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)
Study NCT03155256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided injection of coils
Description: First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).